BioSpace News Archive

Collins, a former member of the Innate Immunotherapeutics Board of Directors, was indicted in 2018 and resigned his seat last year.

For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.

Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the company to spend from $1 billion to $5 billion each quarter this year as it plans to bolster its pipeline.

“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline,” said Ugur Sahin, co-founder and chief executive officer of BioNTech.

Posimir is a non-opioid being developed for post-surgical pain. It is designed to be injected into the surgical site, where it delivers bupivacaine for up to three days post-surgery.

January isn’t a particularly busy month for PDUFA dates for the U.S. Food and Drug Administration, with only two scheduled for the month. Here’s a look.

There were plenty of clinical trial announcements this week. Here’s a look.

I-Mab announced the pricing of its initial public offering of 7,407,400 American Depositary Shares, each ten ADSs representing twenty-three ordinary shares of the Company, par value US$0.0001 per share, at US$14.00 per ADS, assuming the underwriters do not exercise their option to purchase additional ADSs.

Deal expands Life Sciences services and solutions portfolio to enable customers worldwide to accelerate life-changing innovations and improve patient outcomes and access

Iterum Therapeutics plc announced that it has entered into a securities purchase agreement, dated as of January 16, 2020, with a group of accredited investors for an approximately $51.9 million private placement, which is expected to close within five business days of the execution date, subject to the satisfaction of customary closing conditions.